Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia

Basit Öğe Kaydı
dc.contributor.authorKockan, Betul
dc.contributor.authorToptas, Tayfur
dc.contributor.authorAtagunduz, Isik
dc.contributor.authorTuglular, Ayse Tulin
dc.contributor.authorOzer, Ayse
dc.contributor.authorAkkiprik, Mustafa
dc.date.accessioned2024-03-13T10:33:17Z
dc.date.available2024-03-13T10:33:17Z
dc.date.issued2018
dc.departmentİstanbul Beykent Üniversitesien_US
dc.description.abstractThe present study aimed to detect the frequency of kinase domain (KD) mutations in order to evaluate their clinical significance and functional importance in 45 patients with chronic myeloid leukemia (CML) who were resistant to imatinib therapy. Sanger sequencing was used (45 patients), along with allele-specific oligonucleotide polymerase chain reaction (ASO-PCR; 3 patients), for the screening of mutations. BCR/ABL KD was amplified by nested PCR and sequencing was performed. Secondly, ASO-PCR was performed to confirm the results of the sequence analysis for E255K mutations. Mutations were detected in 11/45 patients (24.44%) via Sanger sequencing. D241G (4.4%), C369C (4.4%), K285N (2.2%), A380T (2.2%) and A366V (2.2%) mutations were detected. E255K (8.8%) was detected by ASO-PCR and Sanger sequencing. Mutations are a primary reason for suboptimal responses, loss of response and resistance to imatinib. In particular, the E255K mutation, which is characterized by resistance to imatinib and nilotinib, was detected in four patients. Analyzing the mutations and monitoring patients with CML may improve their prognosis and survival rate. ASO-PCR assays will be beneficial for the routine monitoring of mutations.en_US
dc.description.sponsorshipMarmara University [SAG-C-YLP-110315-0057]en_US
dc.description.sponsorshipThe present study was supported by the Scientific Research Projects Committee (grant no. SAG-C-YLP-110315-0057) at Marmara University.en_US
dc.identifier.doi10.3892/ol.2017.7606
dc.identifier.endpage2424en_US
dc.identifier.issn1792-1074
dc.identifier.issn1792-1082
dc.identifier.issue2en_US
dc.identifier.pmid29434953en_US
dc.identifier.scopus2-s2.0-85038420721
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2419en_US
dc.identifier.urihttps://doi.org/10.3892/ol.2017.7606
dc.identifier.urihttps://hdl.handle.net/20.500.12662/3864
dc.identifier.volume15en_US
dc.identifier.wosWOS:000426145100052
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpandidos Publ Ltden_US
dc.relation.ispartofOncology Lettersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectchronic myeloid leukaemiaen_US
dc.subjectbreakpoint cluster region abelson kinase domainen_US
dc.subjectmutationen_US
dc.subjectimatinib resistanceen_US
dc.subjectDNA sequencingen_US
dc.titleMolecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu